Prof. Masafumi Ihara's presentation highlights the growing Alzheimer's disease burden in the Asia-Pacific region, emphasizing the need for disease-modifying treatments like Lecanemab and Donanemab. These treatments aim to slow the progression of Alzheimer's disease, necessitating careful patient selection and addressing critical barriers to ensure equitable access and effective implementation in real-world settings.
Did you find this case study useful? Let us know your thoughts via this short questionnaire...